Is the price fair?
What ARQT's price assumes
Arcutis Biotherapeutics, Inc. trades at 120× earnings against 32.4× for the median Biotechnology name, more expensive than its own group.
120
Trailing P/E · Biotechnology median 32.4 · 3.70× the median: the market pays up for this one
- Price / sales
- 0.01
Price / sales · as of 2026-Q1
- Free cash flow yield
- 1.2%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +25%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / book2026-Q1
- 0.02
- EV / EBIT2026-Q1
- 24.2
- EV / sales2026-Q1
- 0.19
- Healthcare median P/E362 names
- 31.5
- Biotechnology median P/E158 names
- 32.4
- Free cash flow, trailing twelve months
- $39M
- Market capitalisation
- $3.28B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.